Malignant cells purified from nine CTCL patients were incubated with BET inhibitor JQ1 alone or in combination with the BCL2 inhibitor venetoclax, or one of two HDAC inhibitors, vorinostat or romidepsin, to assess for synergy by the cell viability assay, and hill slopes and IC50 values calculated. Here, DNER is linked to primary cutaneous T-cell non-Hodgkin lymphoma.